Lipid Recovery After LVAD Implantation suggest a positive impact of continuous-flow LVAD support on other metabolic derangements of the decompensated HF state, including improvements in glycemic control for patients with diabetes mellitus, and improved insulin and adiponectin resistance. 18, 19 Therefore, we sought to define the impact of LVAD implantation on lipid profiles in advanced HFrEF and to determine whether changes in cholesterol levels after LVAD implantation affect survival during LVAD support.
Methods

Patient Cohort
The retrospective study cohort was assembled from 2 high-volume LVAD implantation centers, Cleveland Clinic and Columbia University Medical Center. Each cohort included all adults (≥18 years at the time of surgery) who underwent primary continuous-flow LVAD implantation (Heartmate II or Heartware heartware ventricular assist device) within a specified time period (January 1, 2006 to December 31, 2013 for Cleveland Clinic and October 1, 2006 to October 8, 2013 for Columbia University) and who had ≥2 total cholesterol results falling within the specified 3-monthly time points (±30 days) during the period of LVAD support. Lipid values were collected within the period 9 months before LVAD implant until death on LVAD support, transplantation, LVAD explantation, transition of follow-up care to another institution (n=11 patients), or administrative censoring (March 1, 2014 Cleveland Clinic, September 1, 2014 Columbia University). If the LVAD was replaced with a new pump, the complete period of both the pump implantations was counted as the total duration of LVAD support. Patient demographics, clinical data, and additional laboratory values were also recorded, as well as the dates of death on LVAD support. Mortality outcomes were recorded until heart transplantation, LVAD explantation, transition of follow-up care to another institution, or administrative censoring. Total mortality after transplantation or explantation was also collected until censoring at each site. Institutional Review Board approval was obtained separately at each site, and the requirement for informed consent was waivered at both institutions.
Analysis of Baseline Characteristics and Univariate Outcomes
Preimplantation demographics, clinical and laboratory characteristics were tabulated both by site and as a combination of patients from both sites. The duration of LVAD support, time from LVAD implantation to mortality/censoring, and frequency of transplantation were also tabulated for the combined group. Comparisons by site were made by Wilcoxon-Mann-Whitney tests (with normal approximation) for continuous data, due to non-normal distributions of some variables, and Fisher exact tests for categorical data. Analyses were performed using SAS release 9.4 (SAS Institute, Cary, NC).
Analysis of Change in Lipid Variables
Total cholesterol, LDL, HDL, and triglyceride results were grouped by their proximity to 3-monthly time points before and after implantation (LVAD implantation designated time 0). Each time point incorporated values sampled±30 days from specified reference time. The total time interval examined extended from 300 days pre implantation to 300 days post implantation. The median and interquartile ranges of these cholesterol measurements over time were displayed graphically and in tabular format. Total cholesterol, LDL, HDL, and triglyceride levels were each compared between time intervals relative to LVAD implantation. Lipid values were evaluated for normality, and accordingly, comparisons were performed with the Wilcoxon matched-pairs signed-rank test between the time 0 point and each other time points. These analyses were performed using GraphPad Prism version 6.0b for Mac (GraphPad Software, La Jolla, CA).
Impact of Lipid Variables on Survival
To examine the relationship between mortality and cholesterol level, we compared the median lipid values at 3 months post implantation for patients who survived LVAD support to transplantation, explantation, or administrative censoring versus those patients who expired on LVAD support. The 3-month time point was chosen because the comparisons described above showed the greatest increase in cholesterol level occurred between time point 0 and +3 months. We then constructed a Kaplan-Meier plot with log-rank testing for significance, dividing the cohort into 2 halves based on the binary definition of lipid recovery (curve constructed with GraphPad Prism version 6.0b for Mac). Lipid recovery was defined as a median or greater change in lipid level from time 0 (implantation) to 3 months post implantation. The same analysis was also repeated for the LDL, HDL, and triglyceride variables. We also assessed the impact of lipid levels on total mortality after LVAD implantation by including the total survival time right until administrative censoring for all patients. Baseline characteristics were compared for patients with/without cholesterol recovery at 3 months post implantation, using Wilcoxon-MannWhitney tests and Fisher exact tests. Only patients who survived to 90 days post-LVAD implantation were included in these analyses.
To determine the independent relationship between survival and recovery from low pre-LVAD cholesterol, we constructed a series of Cox proportional hazards models (PROC PHREG SAS release 9.4, SAS Institute, Cary, NC, using Efron method for examination of ties). The time period analyzed by the Cox models was from 90 days post-LVAD implantation, because subjects needed to have survived to 3 months post implantation to have a qualifying 3-month cholesterol level and hence were not at risk of mortality before 90 days post implantation. The covariate of primary interest was cholesterol recovery (presence/absence of a change in cholesterol from baseline to 3 months post implantation ≥median). We also, in turn, substituted the baseline cholesterol, the change in cholesterol from baseline to 3 months, and the absolute value of cholesterol at 3 months post implantation, as the primary covariate. These 4 models were each replicated for the LDL, HDL, and triglyceride data. Triglyceride values were positively skewed and so this variable was log transformed when used as a continuous variable.
Adjusted Cox models were constructed with the addition of key clinical variables likely to have a significant impact on survival after LVAD implantation. Model covariates were selected from the variables that were most unequally distributed with/without cholesterol recovery including baseline cholesterol to adjust for the pre-LVAD lipid status. Preoperative statin use (or other potent lipid-lowering therapy) was added as an extra covariate to determine whether statins changed the model fit for the relationship between cholesterol recovery and mortality. This was judged by comparing the respective Akaike information criteria values (rather than −2 logL, to account for the difference in the number of model covariates) for the models with and without statins.
The proportional hazards assumption of the Cox model for the binary variable of cholesterol recovery (presence/absence of a change in cholesterol from baseline to 3 months post implantation ≥ median) was assessed using the Epanechnikov Kernel-smoothed hazard function. The proportional hazards assumption for other variables was tested using Schoenfeld residuals and assessing the Pearson correlation coefficients (and their corresponding P values) between the residuals and the ranks of the observed failure times. Nonlinearity of the continuous covariates was also explored. The significance level of all tests was set at 0.05.
A threshold total cholesterol level at 3 months that best predicted future survival during LVAD support was sought. This was achieved using the effect statement in proc phreg with unadjusted and adjusted Cox proportional hazards models to visually determine the mortality hazard ratio (HR) across a spectrum of values for the cholesterol level at 3 months post-LVAD implantation. Finally, to determine possible mechanisms of the observed changes in lipids after LVAD implantation, we calculated the Spearman correlation coefficients (because of non-normal distribution) between baseline and 3-month percent change in cholesterol, with percent change in albumin, bilirubin, and creatinine, respectively.
Results
There were 332 LVAD implants at Cleveland Clinic and 273 at Columbia University Medical Center, during the specified date ranges. A total of 295 HeartMate II and Heartware heartware ventricular assist device recipients met the inclusion criteria of 2+ total cholesterol results falling within the specified time ranges around 3-monthly time points (±30 days) during LVAD support (n=113 Cleveland Clinic and n=182 Columbia University Medical Center). The median age at implantation in the combined cohort was 59 years and 18% were female (Table 1) . Diabetes mellitus was diagnosed preoperatively in 39%, 54% were taking a statin before LVAD implantation and 49% had an ischemic HF cause. Sixty-seven percent of LVADs were implanted with a bridgeto-transplantation strategy.
Some of the laboratory characteristics suggested a higher preoperative risk profile in the Cleveland Clinic patients (lower hemoglobin, platelets, and albumin; higher bilirubin and transaminases; Table 1 ). Cleveland Clinic patients also had slightly lower median total cholesterol (116 versus 129 mg/dL, P=0.04) and LDL (63 versus 69 mg/dL, P=0.02) at baseline. Median duration of LVAD support was 427 days (14 months) and overall 48% of patients were transplanted (median LVAD support duration was lower and the proportion transplanted higher at Columbia University Medical Center, Table 2 ). Twenty-one percent of patients died on LVAD support, of which 9 patients died before 90 days post implantation (range 3 days to 51 days post implantation).
Analysis of Change in Lipid Variables
There was a significant increase in all 4 lipid variables from baseline (time of implantation±30 days) to 3 months±30 days post-LVAD implantation ( Table 3) . The median cholesterol, LDL, HDL, and triglyceride values were significantly higher at 3, 6, 9, and 12 months post implantation, compared with peri-implantation, with the biggest increase seen between implantation and 3 months (Figure 1) . Therefore, further analyses focused on the 3-month post implantation time point 
Impact of Lipid Variables on Survival
Patients who survived on LVAD support to reach cardiac transplantation, LVAD explantation, or administrative censoring had a significantly higher total cholesterol at 3 months post implantation than patients who expired on LVAD support (Figure 2) . Patients who achieved a median or greater change in cholesterol level from baseline to 3 months (±30 days) post-LVAD implantation were younger, more likely to have a nonischemic HF cause and a bridgeto-transplantation strategy and had a lower LVEF than those who did not achieve cholesterol recovery (Table 4) . The recovery group also had significantly lower baseline lipid levels, hence the inclusion of baseline cholesterol in the multivariable models below.
On dividing the cohort into halves at median change values, patients with greater recovery of total cholesterol or triglycerides at 3 months post implantation had significantly lower unadjusted mortality (log-rank P=0.03 and P=0.02, respectively; Figure 3 ). This mortality association was not (mortality from 3 months onwards for fair comparison; Table 5 ). These results were unchanged when the analysis was broadened out to include all patients with baseline lipid results, not just those with 3-month data (data not shown). However, the binary variable of total cholesterol recovery-defined as change from time 0 to 3 months post-LVAD implantation that was greater or equal to the median change-strongly predicted survival during LVAD support (unadjusted HR, 0.445; 95% confidence interval, 0.212-0.932; P=0.03). In addition, both change in cholesterol (from time 0-3 months post implantation) and absolute cholesterol levels at 3 months (±30 days) post-LVAD implantation were significantly associated with lower mortality during LVAD support. Triglyceride recovery was also associated with lower mortality during LVAD support (Table 5) . When adjusted for baseline age, ischemic HF cause, bridge-to-transplantation status, LVEF, and cholesterol at baseline, the change in total cholesterol from baseline to 3 months post-LVAD remained an independent predictor of survival on LVAD support (Table 6 ). Patients with cholesterol recovery had a 76% lower adjusted mortality hazard during LVAD support compared with patients without recovery ( Table 7) . The continuous variable of total cholesterol at 3 months post implantation was also significantly associated with survival during LVAD support (adjusted HR, 0.978 per 1 mg/dL; 95% confidence interval, 0.967-0.990; P<0.001). Adjusted models were not constructed for the other lipid variables because of the small numbers available for these analyses.
The 3-month total cholesterol threshold for transitioning into a more favorable mortality hazard during LVAD support was ≈130 mg/dL, with the lowest adjusted mortality hazard occurring ≈170 mg/dL (Figure 4 ). Despite this nonlinear relationship, quadratic and spline functions did not improve the fit for the 3-month cholesterol Cox model, as judged by the Akaike information criteria. The association between higher cholesterol after LVAD implantation and favorable survival was unaffected by preoperative statin therapy, and there was no significant difference in the 3-month post-LVAD cholesterol in those with or without statin therapy-median 153 (123, 184) mg/dL versus 147.5 (126, 177) mg/dL, respectively, P=1.0. To further explore the impact of statins on mortality, we also expanded the adjusted model for the outcome of cholesterol recovery with the addition of preoperative statin use as a covariate. The addition of statin use to the model did not improve the model fit (Akaike information criteria, 253.68 in the original model and 253.09 with statin covariate) and did not change the HR for 3-month cholesterol. There was no significant effect of preoperative statin use on mortality (HR, 0.528; 95% confidence interval, 0.243-1.148; P=0.10).
To explore possible mechanisms for the observed survival advantage associated with cholesterol recovery, we examined the Spearman correlation coefficients for the percent change in cholesterol from baseline to 3 months post-LVAD with the percent change in creatinine, albumin, and bilirubin. These variables were chosen because they are markers for potential mechanisms by which the survival effect of cholesterol recovery could be mediated. There was a weak but significant correlation with change in albumin (r=0.196, P=0.03). When percent changes of these 3 variables were placed into a Cox proportional hazards model along with percent change in cholesterol from baseline to 3 months, the percent change in cholesterol retained its significance as a mortality predictor (P=0.04) and was the only significant predictor.
Discussion
Our observation of recovery in the lipid profile during LVAD support builds on previously described improvements in insulin resistance and glycemic control for patients with diabetes mellitus. 18 Reduced myocardial levels of toxic lipid intermediates post-LVAD were also demonstrated in a small subgroup of patients within this study. 20 Despite the deranged and insulin-resistant metabolic state of advanced HF, 19, 21 no existing HF therapies specifically target the progressive deterioration in lipid and glucose homeostasis. There is growing interest in the possibility that normalization of the systemic metabolic milieu and myocardial substrate delivery may improve HF survival ( Figure 5 ). This cholesterol recovery data support lipid and glucose hemostasis as a potential target for the development of novel metabolic HF therapies. 22 Therapies Figure 4 . Spline function curve for the impact of cholesterol level at 3 mo after left ventricular assist device (LVAD) implantation on mortality during LVAD support. The hazard of mortality reaches a lower threshold around a total cholesterol level of 130 mg/dL at 3 mo post-LVAD implantation. The nadir for the hazard of mortality is around 170 mg/dL. The spline curve adjusted for age, ischemic heart failure cause, ejection fraction, bridge-to-transplantation strategy, and baseline cholesterol is displayed. Figure 5 . A hypothesis for metabolic recovery after left ventricular assist device (LVAD) implantation in advanced heart failure. LDL indicates low-density lipoprotein.
such as trimetazidine, which inhibits myocardial fatty acid oxidation, improve whole-body insulin sensitivity and raise HDL levels and has been associated with improvements in HF symptoms and myocardial function. 23, 24 Nevertheless, our retrospective analysis does not exclude the possibility that cholesterol recovery is simply a bystander of improved overall metabolic state after hemodynamic improvement.
Second, the impact of low cholesterol levels during LVAD support is clinically relevant in refining LVAD candidate selection and optimization. Cachectic and malnourished patients are at higher risk of mortality during LVAD support. 15, 25 Given the widespread adoption of LVAD therapy and the increasingly comorbid status of LVAD recipients, preoperative nutritional interventions warrant prospective evaluation. Serum cholesterol may be a useful biomarker of the catabolic state. As demonstrated in this study, many advanced HF patients remain on statins at the time of LVAD implantation and beyond, despite relatively low cholesterol levels. A potential role of statin therapy cessation in select advanced HF patients warrants prospective evaluation.
Study Limitations
Our study is limited by its retrospective design and reliance on lipid results obtained at the discretion of healthcare providers during routine clinical care. Patients with extremes in cholesterol values or greater clinical instability may be biased toward greater frequency of lipid level collection. In addition, patients who did not survive the early postoperative period would not have lipid data available for the analyses based on the 3-month time point, which would likely bias the impact on mortality toward the null. The analytic cohort represents only a subset of the total cohort of patients receiving LVADs at the 2 centers, because more than half of the patients did not have lipid results at the specified time points for inclusion in the retrospective cohort. It is possible that the noncholesterol lipid analyses, particularly the Cox model for LDL recovery, were underpowered and would have shown significant associations if the sample size were larger.
This cohort represents the experience of only 2 tertiary care centers, and it is possible that our findings may not be applicable to all continuous-flow LVAD recipients. In addition, our analyses are restricted to patients who were both willing and medically approved for LVAD implantation, which may have introduced a selection bias that excludes the most cachectic HFrEF patients, patients with poorly controlled diabetes mellitus or morbidly obese individuals.
Conclusions
The initiation of continuous-flow LVAD support in advanced systolic HF is associated with significant recovery of total cholesterol, LDL, HDL, and triglyceride levels, and a reversal of the lipid paradox. A greater cholesterol change from baseline to 3 months and a higher absolute cholesterol level at 3 months post implantation were both associated with greater survival during LVAD support. This is despite the absence of a negative effect of low preoperative cholesterol in this cohort. This novel finding is important both in providing insights into the mechanisms underlying the positive impact of LVAD implantation on survival in advanced HF and also in further refining patient selection and optimization for LVAD support.
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